In vivo evaluation of [F-18]FEAnGA-Me Antunes, Inês F.; Haisma, Hidde J.; Elsinga, Philip H.; Sijbesma, Jurgen W. A.; van Waarde, Aren; Willemsen, Antoon T. M.; Dierckx, Rudi A.; de Vries, Erik F. J. a b s t r a c t
In vivo evaluation of [ 18 F]FEAnGA-Me: a PET tracer for imaging β-glucuronidase (β-GUS) activity in a tumor/inflammation rodent model 1 
. Introduction
Glucuronide-drug conjugates exhibit lower toxicity towards normal cells than the corresponding native drugs. However, glucuronide-drug conjugates are susceptible to enzymatic cleavage by β-GUS, resulting in the in situ generation of highly cytotoxic drugs. Since tumors and inflammatory lesions have increased levels of β-GUS, glucuronide conjugates have been investigated as tools to deliver drugs to the target site.
For a better understanding of the mechanisms of action and metabolic conversion of these prodrugs, we have recently synthesized a radiopharmaceutical, 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-β-D-glucopyronuronate ([ 18 F]FEAnGA), for noninvasive PET imaging of extracellular β-GUS activity [1] . Micro-PET with [ 18 F]FEAnGA could clearly visualize enhanced β-GUS levels, in particular in large tumors with necrotic areas, whereas uptake in other organs was very low (except kidneys and bladder). The distribution volume (DV T ) of [ 18 F]FEAnGA in tumors correlated well with the conversion of [ 18 F]FEAnGA by the β-GUS enzyme. However, because of the highly hydrophilic character of [ 18 F]FEAnGA (logD = −1.61), the PET tracer is very rapidly excreted via the kidneys into the urine. This rapid renal clearance resulted in a relatively low absolute tracer uptake in the tumor [2] .
The disadvantage of rapid renal clearance was also found for prodrugs such as DOX-GA3 and DNR-GA3 [3, 4] . To reduce renal clearance, de Graaf et al. converted DOX-GA3 to its methyl ester (DOX-mGA3), which is substantially less hydrophilic [5] . The glucuronide conjugate is negatively charged at physiological pH, whereas the corresponding methyl ester is a neutral molecule. Slow release of DOX-GA3 through conversion of its methyl ester by esterase activity in blood resulted in a prolonged circulation half-life of DOX-GA3. Intravenous administration of DOX-mGA3 in tumor bearing mice resulted in a 2.7-fold increase in the delivery (area under the concentration versus time curve (AUC) from 0.5 to 2 h) of doxorubicin to the tumor, as compared to administration of DOX-GA3. Therefore, we hypothesized that a similar approach could increase the delivery of [ 18 F]FEAnGA as well. Therefore, we now synthesized its less hydrophilic methyl ester of [ 18 F]FEAnGA, called [ 18 F]FEAnGA-Me. When administered in vivo, the methyl group of [ 18 F]FEAnGA-Me should be removed by carboxylesterase activity in plasma to give the original PET tracer [ 18 F]FEAnGA, which could in turn be activated by β-GUS at the target site (Scheme 1) and release 2-[ 18 F]fluoroethylamine ([ 18 F]FEA). The slow release of [ 18 F]FEAnGA after administration of [ 1 8 F]FEAnGA-Me might result in improved pharmacokinetics of the PET tracer in vivo, resulting in a higher absolute tracer uptake in tumors.
In the present study, we describe the labeling of [ 18 F]FEAnGA-Me and its stability in vitro. In addition, we analyzed the in vitro conversion of [ 18 
Materials and methods
Reagents and solvents were obtained from commercial suppliers (Sigma-Aldrich and Fluka, Zwijndrecht, the Netherlands and Merck, Darmstadt, Germany) and used without further purification. The reference compounds, FEAnGA-Me and FEAnGA were prepared as previously described [1] . For radiolabeled compounds, the detection on the TLC was performed with Cyclone phosphor storage screens (multisensitive, Packard, PerkinElmer Life and Analytica Science). These screens were exposed to the TLC strips (60 s for in vitro experiments and 20 min for in vivo experiments), subsequently read out using a Cyclone phosphor storage imager (PerkinElmer) and analyzed with OptiQuant software. HPLC purifications were performed with an Elite LaChrom VWR Hitachi L-2130 pump system using a Phenomenex Prodigy C18-column, connected to a UVspectrometer (Elite LaChrom VWR Hitachi L-2400 UV detector) set at 254 nm and a Bicron frisk-tech radiation detector. Radioactivity measurements for logD determination and cell studies were done using an automated gamma counter (Compugamma, LKB Wallac). Absorbance measurements in the enzyme assays were performed with a UV-spectrophotometer (Waters 2487 dual wavelength absorbance detector). ]. To this solution, 1 mL acetonitrile was added and the solvents were evaporated at 130°C. The [ 18 F]KF/Kryptofix complex was dried 3 times by the addition of 0.5 mL acetonitrile, followed by evaporation of the solvent.
[ 18 F]FEA was prepared by fluorination of N-[2-(toluene-4-sulfonyloxy)-ethyl]-phtalimide (30 mg, 0.09 mmol) in 500 μL of acetonitrile at 110°C, followed by deprotection with hydrazine hydrate (50 μl, 1.03 mmol) as described in the literature [6] . The resulting amine was distilled at 75°C into an ice-cold solution of 1 (5 mg, 0.009 mmol) in acetonitrile (0.2 mL). The mixture was allowed to react at room temperature for 30 min. The product was dried at 40°C for 2 min under a gentle argon flow. Deprotection of the hydroxyl groups was done by addition of 30 μL 0.5 M NAOMe/MeOH and incubation for 7 min at room temperature. The product was neutralized by the addition of 20 μL 1 M AcOH, diluted with 2 mL of distilled water and purified by HPLC using a semi-preparative Prodigy C 18 reverse-phase column ( [2] with a specific activity of 149 ± 33 GBq/μmol and the radiochemical purity was always N95%. 
Stability of [ 18 F]EAnGA-Me

Distribution coefficient (Log D 7.4 )
To determine the Log D 7.4 of [ 18 F]FEAnGA-Me an aliquot of 100 μL of HPLC purified [ 18 F]FEAnGA-Me solution was added to a mixture of n-octanol/PBS (4 mL:4 mL) at pH 7.4. The tubes were vortexed at room temperature for 30 s, followed by 30 min shaking in a water bath at 37°C. Aliquots of 1 mL were drawn from both the n-octanol and aqueous phase. Radioactivity in both samples was counted using an automated gamma counter. The experiments were performed in triplicate. Scheme 1. General mechanism of activation of the prodrug tracer.
In vitro hydrolysis of FEAnGA-Me
To a solution of 0.1% bovine serum albumin (BSA), 200 μL (15U) of carboxylesterase of porcine liver (Sigma-Aldrich) and/or 10 μL (74U) Escherichia coli β-GUS (E. coli β-GUS) in 950 μL PBS (pH = 7), 50 μL of a 0.004 M solution of FEAnGA-Me was added (total volume 1 mL). The solutions were incubated in a water bath at 37°C and 100 μL samples were collected at different time points between 1 min and 60 min after the start of incubation. The enzymatic activity was stopped by dilution of the samples in 300 μL of acetonitrile and cooling of the samples in ice. The release of 4-hydroxy-3-nitrobenzyl alcohol (HNBA) (ɛ = 3460 M −1 cm −1 ) was monitored by measuring the UV absorbance at 412 nm. The experiment was performed in duplicate.
In vitro hydrolysis of [ 18 F]FEAnGA-Me by plasma
To a 0.4 mL solution of PBS (pH = 7.4), or rat plasma with or without 10 μL (74U) Escherichia coli β-GUS, 0.1 mL of HPLC purified [ 18 F]FEAnGA-Me (2 ± 0.2 MBq; 11 ± 1 pmol) was added. The solutions were incubated in a water bath at 37°C and 2 μL samples were collected at different time points between 30 s and 60 min after the start of incubation. The degradation of the radiolabeled [ 18 F] FEAnGA-Me was followed by radio-TLC (eluent: MeCN/H 2 O 7:3). After elution, the TLCs were analyzed by phosphor storage imaging as described above. The experiment was performed in duplicate.
Cellular uptake of [ 18 F]FEAnGA-Me
C6 glioma cells were maintained in 5 mL Dulbecco's Modified Eagle Medium (DMEM) supplemented with 7.5% fetal bovine serum (FBS) in 25 cm 3 culture flasks. Cells were grown in a humidified atmosphere containing 5% CO 2 and were passaged every 3-4 days. For uptake experiments, cells were plated in triplicate in a 12-well plate at a density of 7 × 10 5 cells per well. After 24 h, the medium was discarded and 1 mL of PBS-GMC buffer (5.6 mM D-glucose, 0.49 mM MgCl 2 and 0.68 mM CaCl 2 in 100 mL phosphate-buffered saline (PBS)) per well was added, followed by the addition of 200 μL [ 18 F]FEAnGA-Me (ca. 250 kBq; ca. 1 pmol). In each series of 3 wells, either β-GUS (740 U), esterase (15 U) or a combination of β-GUS (740 U) and esterase (15 U) was added. After 60 min of incubation at 37°C, the medium was collected, the cells washed with cold PBS (3 × 1 mL/well), harvested with trypsin (250 μL) and resuspended in 1750 μL of DMEM (total volume 2 mL/well). The cell suspensions and the medium were collected separately for each well and the radioactivity was measured using a gamma counter. For each well, the medium was analyzed for conversion of [ 18 F]FEAnGA-Me to [ 18 F]FEA by radio-TLC as described above.
Animal model
Wistar rats (6-8 weeks old) were obtained from Harlan (Lelystad, the Netherlands). The animals were provided with standard laboratory chow and tap water ad libitum. All studies were carried out in compliance with the local ethical guidelines for animal experiments. The protocols were approved by the Animal Ethics Committee of University of Groningen. The tumor-inflammation model was described previously [7, 8] . Briefly, C6 glioma cells [2-3 × 10 6 cells in a 1:1 mixture of Matrigel and Dulbecco's minimal essential medium containing 7.5% fetal bovine serum] were subcutaneously injected into the right shoulder of male Wistar rats. At day 12, 0.1 mL of turpentine was intramuscularly injected into the thigh of the left hind leg of the same animal.
PET imaging and ex vivo biodistribution studies
In the tumor-inflammation model (n = 14), PET scans were performed on day 13 after inoculation. The rats were anesthetized with 2% isoflurane (5% induction, 2% maintenance; Pharmachemie BV, the Netherlands) and positioned in the small animal PET camera (Siemens, Focus 220) with the tumor in the field of view. Owing to
the small field-of-view of our microPET camera, it was not possible to obtain a whole body scan of the rat. Although the camera is equipped with a continuous bed motion option, this method is not suitable to obtain quantitative information, because attenuation correction is not feasible in this mode and the bed motion is relatively slow with respect to tracer kinetics, especially at the early time points. Moreover, imaging of the inflammatory lesions in the leg is difficult due to artifacts created by the high uptake in bladder, which would also be in the field-of-view. For the above mentioned reasons the PET scan was only performed in the tumor region. A transmission scan of 515 s with a Co-57 point source was obtained for the correction of attenuation and scatter by tissue. After the transmission scan was completed, [ 18 F]FEAnGA-Me (8.6 ± 0.7 MBq; 46 ± 4 pmol) or [ 18 F]FEAnGA (12.5 ± 2.2 MBq; 84 ± 5 pmol) was injected via the penile vein. Simultaneously with the injection of the PET tracer, an emission scan of 60 min was started. After completion of the emission scan, the rats were sacrificed by extirpation of the heart, while still being under deep isoflurane anesthesia. Several tissues, peripheral organs, tumor and inflamed muscle were excised and blood was collected. Plasma and red blood cells were obtained from the blood sample by centrifugation (20 min at 6000 g). All tissue samples and plasma were weighed and the amount of radioactivity was determined with a gamma counter (LKB Wallac, Turku, Finland). Tracer uptake is expressed as standardized uptake value (SUV), which is defined as: [tissue activity concentration (MBq/g) × body weight (g) / injected dose (MBq)]. It was assumed that 1 cm 3 of tissue equals 1 g.
Pharmacokinetics studies
Wistar rats (n = 22) bearing a C6 tumor were anesthetized with isoflurane (5% induction, 2% maintenance) and a canula was inserted into the femoral artery for collection of blood samples. Animals were placed in the PET camera with the tumor in the center of the field of view. Simultaneously with the injection of either [ 18 F]FEAnGA-Me (7.0 ± 0.9 MBq; 38 ± 5 pmol) or [ 18 F]FEAnGA (7.4 ± 0.5 MBq; 50 ± 3 pmol), a dynamic PET scan was started as described above. During the 60 min PET scan, blood samples of 100 μL were taken at 15, 30, 45, 60, 75, 90, 120, 150, 300, 450, 600, 1800, 3600 s after tracer injection. After a blood sample was taken, 100 μL of heparinized saline was injected via the artery canula to prevent large changes in blood pressure. The blood samples were centrifuged at 6000 rpm for 10 min and 50 μL of plasma was collected. The activity in plasma was measured with a gamma counter (LKB Wallac, Turku, Finland). The plasma-activity curves were corrected for decay. The rats were sacrificed after the scans and the tumors were excised and weighed. The radioactivity in the tumors was measured with a gamma counter and converted to SUV.
PET image analysis
The list mode data of the emission scans were separated into 17 frames. Emission sinograms were iteratively reconstructed (OSEM2D, 4 iterations, 16 subsets) after being normalized, corrected for attenuation, and corrected for radioactive decay. Three-dimensional regions of interest (3D-ROIs) were generated automatically using the intensity threshold method from Inveon Research Workplace software package (Inveon, Siemens, USA) [9, 10] . Briefly, the last 9 frames (10-60 min) were summed and an ROI of the viable part of the tumor was generated automatically with a 50% threshold using a region growing method, i.e. only pixels with tracer uptake greater than 50% of the maximum value within the lesion were included. The resulting ROIs were used on the original data set to create the corresponding 0-60 min time-activity curves (TACs). A second ROI was drawn around the whole tumor to obtain the total tumor volume (V t ; cm 3 ), using standard software (Inveon, Siemens, USA). In those animals where plasma input curves were obtained through arterial sampling, pharmacokinetic modeling of the tissue TACs was performed using standard software (Inveon, Siemens, USA). The graphical Logan model was used to determine the distribution volume, DV T , and a 2 tissuecompartment model fit was used to calculate the rate constants K 1 -k 4 using a free blood volume.
Metabolite analysis
2.5 μL of each plasma sample was collected, applied on a TLC plate (Merck F-254 silica gel) and eluted with acetonitrile/water (7:3). After elution, TLC plates were analyzed by phosphor storage imaging. Exposed screens were scanned with a Cyclone phosphor storage system (PerkinElmer Life and Analytica Science) and the percentage of conversion of [ 18 F]FEAnGA-Me as a function of time was calculated by ROI analysis using OptiQuant software. Part of the tumors (containing both the rim and the necrotic core, 0.12 ± 0.04 g) excised from the sampled animals was homogenized in 2 mL of phosphate buffered saline (PBS). The homogenates were centrifuged (10 min, 3000 rpm, 4°C) and the supernatant was collected and kept on ice. To the supernatant, 2 mL of cold acetonitrile was added to precipitate the remaining proteins. The samples were vortexed for 30 s and centrifuged at 3000 rpm for 10 min at 4°C. A volume of 1.5 mL of the supernatant was added to 1.5 mL of cold NaOH 0.25 M and UV absorption was measured (Waters 2487 dual wavelength absorbance detector, 412 nm, aufs = 0.01). Absorption was converted in the concentration of HNBA, using a calibration curve. The absorption was corrected for the weight (mg) of the tumor sample. The measurements were performed in duplicate.
Statistical analysis
Statistical analyses were performed using Microsoft Excel 2003 and SigmaPlot (version 10.0; SPSS, Inc.). Differences in tumor accumulation between tracers were analyzed using the two-sided unpaired Student's t test. Differences in tracer accumulation between inflamed and healthy muscle were studied in the same animal to reduce variability between animals and therefore were analyzed using the two-sided paired Student's t test. Significance was reached when the P value was b.05. Correlations were calculated with the linear regression algorithm in SigmaPlot and were considered statistically significant whenever R 2 N 0.5 and P b .05. Throughout the manuscript values are presented as mean ± SEM. 
Results
Labeling of [ 18 F]FEAnGA-Me
Properties of [ 18 F]FEAnGA-Me
The stability of [ 18 F]FEAnGA-Me in PBS, was evaluated at 37°C. After 1 h of incubation, radio-TLC analysis showed that 95% of the tracer was still intact while 5% was hydrolyzed to [ 18 F]FEAnGA. We then determined the lipophilicity of [ 18 F]FEAnGA-Me by measuring its n-octanol/water distribution coefficient (LogD) at pH 7.4. The logD of [ 18 F]FEAnGA-Me was found to be −0.58 ± 0.0002.
In vitro hydrolysis of FEAnGA-Me/[ 18 F]FEAnGA-Me
The enzymatic processing of FEAnGA-Me was first studied using commercially available bacterial Escherichia coli β-GUS and porcine liver carboxylesterase. Fig. 1 indicates that incubation of FEAnGA-Me with the combination of esterase and E. coli β-GUS resulted in 80% conversion to FEA and 4-hydroxy-3-nitrobenzyl alcohol (HNBA), while in the presence of E. coli β-GUS alone, only 6% of FEAnGA-Me was converted to FEA and HNBA. This 6% conversion of FEAnGA-Me to FEAnGA in the absence of esterase was probably due to some spontaneous hydrolysis of the ester to the carboxylic acid. The liberation of 4-hydroxy-3-nitrobenzyl alcohol (HNBA) was measured by UV-spectrophotometry at 412 nm.
However, monitoring of the conversion of FEAnGA-Me to FEAnGA was not possible, since neither glucuronide shows UV absorption at this wavelength. Furthermore, we aimed to demonstrate that esterases in plasma are able to hydrolyze the glucuronide ester to the carboxylic acid. Therefore, we continued the hydrolysis analysis with the radioactive compound, [ 18 F]FEAnGA-Me. Radiolabeled [ 18 F]FEAnGA-Me was incubated in rat plasma. After 30 min, 99% of [ 18 F]FEAnGA-Me was converted to [ 18 F]FEAnGA, while no [ 18 F]FEAnGA was generated in 0.1% BSA in PBS. When [ 18 F]FEAnGA-Me was incubated in rat plasma supplemented with E. coli β-GUS, 50% cleavage of the tracer to [ 18 F]FEA was observed within 30 min (Fig. 2 ).
Cellular uptake of [ 18 F]FEAnGA-Me in C6 glioma cells
As depicted in Fig. 3 , the cell-associated radioactivity was significantly increased by 60%, when C6 cells were incubated with [ 18 F] FEAnGA-Me in the presence of both E. coli β-GUS and esterase. After incubation of C6 cells with [ 18 F]FEAnGA-Me, cell-associated activity was not affected by either E. coli β-GUS or esterase alone. Furthermore, the radio-TLC analysis of the medium showed that in the presence of both E. coli β-GUS and esterase the conversion of [ 18 F]FEAnGA-Me to [ 18 F]FEA was 99%, while in the presence of E. coli β-GUS alone there was only 7% of conversion to [ 18 F]FEA. These results suggest that the increase in cell associated radioactivity is related with the conversion of [ 18 F]FEAnGA-Me to [ 18 F]FEA. The latter compound is thought to have a higher tendency to associate to the cells [1, 2] .
In vivo hydrolysis of [ 18 F]FEAnGA-Me
The hydrolysis of [ 18 F]FEAnGA-Me to [ 18 F]FEAnGA by plasma was also studied in tumor bearing rats. After injection into the rat, the fraction of [ 18 F]FEAnGA-Me present in plasma decreased rapidly to 50% in the first 2 min, followed by a plateau phase. After 10 min, [ 18 F] FEAnGA-Me was more slowly converted to [ 18 F]FEAnGA, with still 26% of the radioactivity in plasma being [ 18 F]FEAnGA-Me at the end of the study (60 min) (Fig. 4A) 
PET study and ex vivo biodistribution
To test the potential of [ 18 F]FEAnGA-Me as a PET tracer for detecting β-GUS activity in vivo, a PET study was performed in rats bearing a C6 glioma and sterile inflammation. A microPET scan was performed in these rats after injection of either [ 18 F]FEAnGA-Me (n = 6) or [ 18 F]FEAnGA (n = 8), in order to compare both tracers. In the PET images (summed from 10 to 60 min, Fig. 6 (Fig. 6 ). The accumulation of radioactivity in the viable part of the tumors after [ 18 F]FEAnGA-Me injection reached a maximum at 1.5 min post injection and afterwards decreased exponentially with a half-life of 16 ± 2 min, while after [ 18 F]FEAnGA injection, the accumulation of radioactivity in the viable part of the tumors decreased with a half-life of 24 ± 9 min (Fig. 6 ). In addition, the area under the curve (AUC) of [ 18 F]FEAnGA-Me in tumors (23 ± 6) was similar to the AUC of [ 18 F] FEAnGA in tumors (20 ± 4, P = .65).
To compare the distribution after [ 18 F]FEAnGA-Me or [ 18 F]FEAnGA injection, ex vivo biodistribution studies of both tracers were performed after the PET scan, i.e. at 60 min post injection. After injection of [ 18 F]FEAnGA-Me the uptake (SUV) in most of the peripheral organs was similar to the uptake in these organs after injection of [ 18 F]FEAnGA. However, uptake in the liver and kidneys was 3 times higher after injection of [ 18 F]FEAnGA-Me than after injection of [ 18 F]FEAnGA (P b .05) ( Table 1 ). In the excised C6 tumors (2.35 ± 0.42 g), the uptake (SUV) was 0.13 ± 0.02 at 1 h after injection of [ 18 F]FEAnGA-Me, while tracer uptake was 0.13 ± 0.05 and Fig. 1 . In vitro release of the spacer HNBA from FEAnGA-Me and its quantification by UV absorption due to its yellow color (412 nm). FEAnGA-Me was exposed to either esterase or E. coli β-GUS alone, or a combination of both enzymes. 0.08 ± 0.02 in inflamed and healthy muscle, respectively. When injected with [ 18 F]FEAnGA the uptake was 0.13 ± 0.03 in the excised tumors (2.35 ± 0.65 g) and 0.07 ± 0.02 and 0.04 ± 0.01 in the inflamed and healthy muscles, respectively. The inflammation-to-muscle ratios of both tracers [ 18 F]FEAnGA-Me (1.48 ± 0.22) and [ 18 F]FEAnGA (1.59 ± 0.19) were not significantly different, but the tumor-tomuscle ratios of [ 18 F]FEAnGA-Me (1.85 ± 0.23) were significantly lower than those of [ 18 F]FEAnGA (3.53 ± 0.52, P = .02). 
Pharmacokinetic modeling
The sampled rats were divided in two groups (injected with either [ 18 F]FEAnGA-Me or [ 18 F]FEAnGA) to compare the tracers' pharmacokinetics in vivo.
By applying 50% of SUV max as the threshold, an ROI was obtained representing the viable part of the tumor. The TACs of the viable part of the tumor together with individual plasma radioactivity curves, Logan graphical analysis and a 2 tissue reversible compartment model were used for pharmacokinetic modeling.
The tumor distribution volume, DV T , from the Logan graphical analysis after [ 18 F]FEAnGA-Me injection (0.61 ± 0.06), was not significantly different from the DV T after [ 18 F]FEAnGA injection (0.50 ± 0.04). Similar distribution volumes were also obtained using the 2 tissue compartment modeling ( Table 2 ). 
Discussion
In the last years, interest into the development of radiolabeled markers for the non-invasive evaluation of prodrug-converting enzymes in solid tumors has increased [11] [12] [13] [14] [15] . Knowledge of the prodrug-converting enzyme expression and activity can lead to a better understanding of the mechanism of action and metabolic conversion of the prodrug and could identify sites that are prone to possible side-effects. Eventually, a suitable PET method might allow the selection of patients eligible for β-GUS mediated prodrug therapy.
[ 18 F]FEAnGA is a PET tracer capable of detecting increased release of β-GUS in large solid tumors as well as in inflammatory lesions. However, the renal clearance of [ 18 F]FEAnGA was fast relative to the conversion of [ 18 F]FEAnGA to [ 18 F]FEA resulting in a relatively low tracer uptake in the tumor. Therefore, we synthesized the more lipophilic methyl ester of [ 18 F]FEAnGA, called [ 18 F]FEAnGA-Me and hypothesized that the increase in lipophilicity would prolong the circulation half-life of the tracer which would result in prolonged availability of the tracer for conversion by β-GUS.
The synthesis of [ 18 F]FEAnGA-Me was similar to [ 18 F]FEAnGA, only differing in the deprotection process where NaOMe/MeOH in anhydrous conditions was used instead of aqueous NaOH. This last step was of critical importance with regards to the final yield. In the presence of acetonitrile and NaOMe/MeOH the major compound obtained was [ 18 F]FEAnGA. However, if compound [ 18 F]-2 was dried before adding NaOMe/MeOH, [ 18 F]FEAnGA-Me was obtained in 5% to 10% yield. In addition, [ 18 F]FEAnGA was concomitantly formed in 5%-10% yield. Despite numerous attempts to improve the final yield, we were not able to improve the yield any further. Thus, the final product [ 18 F]FEAnGA-Me was obtained in 5%-10% overall radiochemical yield (corrected for decay, based on [ 18 F]fluoride) with a total synthesis time of 120 min (Scheme 2). The identity of [ 18 F] FEAnGA-Me was confirmed by coelution with a sample of the nonradioactive compound by RP-HPLC. [ 18 F]FEAnGA-Me was found to be completely stable in PBS for at least 1 h.
We anticipated that the methyl group of [ 18 F]FEAnGA-Me could be enzymatically converted to the carboxylic acid of [ 18 F]FEAnGA by esterase in the blood (Scheme 1). Indeed, we showed that [ 18 F] FEAnGA-Me was completely hydrolyzed to [ 18 F]FEAnGA in the FEAnGA-Me, in the presence of both esterase and E. coli β-GUS showed similar accumulation of radioactivity as C6 cells incubated with [ 18 F]FEA itself (0.8%) [2] . and 2 times higher uptake when compared to C6 cells incubated with [ 18 F]FEAnGA, in the presence of E. coli β-GUS (0.4%). However, the cellular uptake of [ 18 F]FEAnGA-Me in control C6 cells (absence of enzymes) was also higher than the uptake of [ 18 F]FEAnGA, suggesting a lower in vitro selectivity of [ 18 F] FEAnGA-Me when compared to [ 18 F]FEAnGA (Fig. 7) .
As expected the lipophilicity of [ 18 F]FEAnGA-Me was found to be 10 fold higher than [ 18 F]FEAnGA. By analogy with the methyl ester DOX-mGA3 which was 3 times less hydrophilic than the original prodrug DOX-GA3, we hypothesized that the administration of the less hydrophilic [ 18 F]FEAnGA-Me would also result in a prolonged circulation of [ 18 F]FEAnGA in rats as compared to direct administration of the highly hydrophilic [ 18 F]FEAnGA.
Houba et al. found that the administration of methyl ester DOX-mGA3 in mice resulted in slow conversion of DOX-mGA3 to the original DOX-GA3 in plasma, resulting in slower plasma clearance and consequently, increased delivery and a higher concentration of DOX at the target site. In contrast to the encouraging results by Houba et al., we did not find any increase in radioactivity accumulation in the tumor after administration of the methyl ester PET tracer [ 18 F] FEAnGA-Me, when compared to the original tracer [ 18 F]FEAnGA. This apparent discrepancy could be explained by differences in the administered dose between the prodrug DOX-mGA (20,000 μg/kg) and the PET tracer [ 18 F]FEAnGA-Me (0.7 μg/kg). Conversion of glucuronide methyl esters by plasma esterases is generally a fast process. In the study by Houba et al., however, the administered dose was suggested to saturate the esterases in plasma, resulting in a relatively slow conversion of DOX-mGA3 to DOX-GA3. In contrast, the administrated amount of the glucuronide ester [ 18 F]FEAnGA-Me in our study was approximately 5 orders of magnitude lower and therefore far below the saturation level of plasma esterases. Indeed, [ 18 F]FEAnGA-Me was rapidly converted to [ 18 F]FEAnGA, as 50% conversion was already achieved within the first two minutes post injection. As a consequence, no difference in plasma AUC of [ 18 F] FEAnGA-Me and [ 18 F]FEAnGA was observed, nor were differences in the clearance half-life between both tracers observed. The ex vivo biodistribution of both tracers indicated similar uptake (SUV) in most of the peripheral organs with the exception of the liver and kidneys, where the uptake was 3 times higher after injection of [ 18 F]FEAnGA-Me when compared with the uptake after injection with [ 18 F]FEAnGA. The uptake in inflamed muscle was 2 times higher after [ 18 F]FEAnGA-Me injection in comparison with the uptake after [ 18 F]FEAnGA injection. However, the uptake in healthy muscle was also 2 times higher in animals injected with [ 18 F] FEAnGA-Me. Thus, the ratio between inflamed and control muscle for the two tracers was similar. These biodistribution results are in agreement with what we found in vitro, where [ 18 F]FEAnGA-Me loses selectivity when compared to [ 18 F]FEAnGA suggesting an increased uptake of the less hydrophilic [ 18 F]FEAnGA-Me in normal tissue. Indeed, also in the pharmacokinetic analysis, no statistical differences were found between the distribution volumes (DV T ) in tumors when injected with one or either tracer.
When injected with [ 18 F]FEAnGA, DV T in tumors is dependent on the [ 18 F]FEAnGA influx (from the plasma to the extracellular space) and its conversion to [ 18 F]FEA and HNBA in the presence of extracellular β-GUS. After [ 18 F]FEAnGA-Me injection the DV T in tumors depends on both [ 18 F]FEAnGA-Me and [ 18 F]FEAnGA influx and the conversion of [ 18 F]FEAnGA to [ 18 F]FEA and HNBA. Therefore, as expected the DV T in the viable part of the tumors correlated well with the HNBA formation after injection of [ 18 F]FEAnGA but did not correlate well with the HNBA formation when injected with [ 18 F] FEAnGA-Me (Fig. 8) .
The pharmacokinetic behavior of [ 18 F]FEAnGA-Me is likely more favorable in man considering the lower levels of esterase in the human body as compared to rats which would increase the availability of the tracer for β-GUS. However, these sustained plasma levels of tracer would ultimately increase the background activity and therefore decrease the contrast between background and targeted region. Therefore, different strategies should be pursued in order to improve the pharmacokinetics of glucuronide PET tracers, such as PET tracers with higher turn over so that the release of the radioactive moiety is faster than the clearance of the tracer, resulting in higher tracer uptake at the target site without increasing the background activity.
Conclusion
[ 18 F]FEAnGA-Me was labeled with [ 18 F]fluoride and has a high in vitro stability in PBS. [ 18 F]FEAnGA-Me proved to be a good substrate for plasma esterase and in the presence of both esterase and E. coli β-GUS is converted to [ 18 F]FEA and HNBA. In contrast to our hypothesis, administration of [ 18 F]FEAnGA-Me did not result in a significantly prolonged circulation of [ 18 F]FEAnGA in rats as compared to the direct administration of [ 18 F]FEAnGA. In fact, due to its lower hydrophilicity, nonspecific uptake of [ 18 F]FEAnGA-Me increased, resulting in a lower target to background contrast. In addition, the 2-step prodrug activation strategy further complicates the mode of action of this radiopharmaceutical and thus complicates the interpretation of the imaging results. Therefore, different strategies, such as the use of prodrug with higher β-GUS turnover should likely be pursuit in order to improve the pharmacokinetics and pharmacodynamics of glucuronide PET tracers. 
